Monday, August 20, 2012    |    |    Archives    |   Advertising   |    CHI Conferences    |     Subscribe       

eCliniqua is now on Facebook! 

Follow us on Facebook for breaking news, upcoming event information and
complimentary downloads.

Quinten's Savoir Faire Approach to Clinical Data Mining
eCliniqua | A rapidly expanding French CRO called Quinten is quietly building an impressive
client roster as it brings an innovative data mining approach to a broad expanse of the drug
development pipeline - from early-stage target identification to its sweet spot in clinical
trials and patient stratification. Read More

Previewing the 2012 Barnett Clinical Summit
eCliniqua | This year's annual Barnett Clinical Summit, which will be held this October,
will focus on the theme of Optimizing Trial Performance, connecting clinical research experts,
sponsors, sites and regulators. Read More

DIA 2012 - Spotlight on eTMFs and Data Analytics (Part II)
eCliniqua | In part 2 of her annual tour of DIA e-clinical technology trends, Ann Neuer
profiles innovative offerings in electronic trial master file (eTMF) solutions and clinical trial
analytics from companies such as NextDocs Corporation, Sitrof Technologies and Comprehend
Systems. Read More


New House Bill to Expose All Clinical Trials in Public Database
|Mass Device | Four House Democrats aim to close loopholes in the U.S. government's clinical
trial reporting requirements to ensure that all human studies are publicly disclosed online.
The proposed Trial & Experimental Studies Transparency Act would require drug makers to
report all studies and results publicly through the website. Read More

Microarray Clinical Trial Is Favorable for a Prenatal Gene Test
New York Times | The use of microarrays for prenatal testing to detect more genetic problems
in a fetus than ever before could be headed toward wider use after encouraging results from a
clinical trial sponsored by the NIH involving 4,400 pregnant women. Read More

Sharp Dip in US Drug Approvals Forecast
Pharma Times | The US Food and Drug Administration (FDA) will approve fewer novel drugs in
2012 than it did last year, as the industry faces a number of ongoing operational risks,
according to a new report.  Read More

Parexel Alliance for Drug Development in South Korea | Parexel International has been chosen by the Korea Drug Development Fund to
help Korean biopharmaceutical companies develop and commercialize health care products
for the global market. Read More